IDEXX Laboratories, Inc. (IDXX) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High Margins ⢠Strong Cash Flow ⢠Rich Valuation IDXX delivers exceptional margins, high returns, and strong cash flow, but its premium valuation, moderate leverage, and only adequate liquidity limit upside and demand execution.
Price Behavior
Key Price Behavior Insights: ⢠Support holding ⢠Lower highs ⢠Resistance ceiling Support Level: $557â$565 Resistance Level: $584â$592 IDXX has been range-bound over the last month, with support holding in the $557â$565 area but repeated failures at $584â$592 signaling fading upside momentum and a need to reclaim the upper-$580s to low-$590s for improvement.
Sentiment & News
Key News Insights: ⢠Diagnostics Expansion ⢠Earnings Momentum ⢠Premium Valuation IDEXX Laboratories is being viewed as a strong growth and momentum stock thanks to diagnostic innovation, recurring revenue, and a positive earnings outlook, though its premium valuation remains a key concern.
AI Summary
IDXX is still a high-quality diagnostics compounder, but the bigger investment question now is whether durable growth from recurring diagnostics and innovation can keep outrunning softer vet traffic and justify a premium valuation that leaves little room for error.
Description
IDEXX Laboratories develops, manufactures, and sells diagnostic instruments, consumables, laboratory services, and practice management software for veterinary, livestock, dairy and water-testing markets worldwide. Its offerings include point-of-care and reference laboratory diagnostics, imaging and monitoring systems, and microbiological water tests, supported by sales, technical service teams and distribution partners. The company also supplies certain human point-of-care analyzers; it was founded in 1983 and is headquartered in Westbrook, Maine.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | IDXX | IDEXX Laboratories, Inc. | Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution. | Closed | -1.8% |